High levels of Bcl-xL or Aurora A have been previously correlated with poor overall survival (OS) and short progression-free survival (PFS) in breast cancer, including TNBC [40,43,44,45,46], but a correlation between co-expression of AURKA and BCL2L1 and TNBC patient survival has not yet been reported. This evidence concerns the gene AURKA and breast carcinoma.